《盈警響號》富智康(02038.HK)料首季虧損收窄3,804萬美元 中期虧損低於去年同期
富智康(02038.HK)發盈警,預計截至今年3月底止第一季度營業額19.4億美元,按年上升9.6%。綜合淨虧損約為3,804萬美元,去年同期為6,248萬美元。
集團預計,截至今年上半年的綜合淨虧損將低於去年同期的1.01億美元。但鑑於多項因素,包括疫情全球大流行及相關限制措施已繼續對零組件之供應、交貨時間及價格、全球供應鏈以及可預見供應時間之長短產生不利之影響;持續進行優化及/或重組所產生之實際及潛在成本、開支及/或虧損;自2017年後期起所面對之具挑戰性境況已持續至2021年。現階段未能合理可能地對集團今年中期業績作出更精確評估。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.